603259 药明康德
2023/12 -
人民幣(K¥)

变动
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
2018/12
人民幣(K¥)
营业总收入40,340,8072.51%22,902,38516,535,43112,872,2069,613,684
减:营业总成本28,708,591-3.67%18,574,51613,928,30410,421,6957,810,966
    其中:营业成本23,728,800-3.84%14,592,25610,253,2767,858,2995,820,983
               财务费用(338,119)36.36%84,082519,80423,96156,210
               资产减值损失(156,509)-11.05%(33,056)(62,642)(1,433)(2,011)
公允价值变动收益(37,809)-104.91%(93,387)52,271(259,257)606,437
投资收益233,84924.42%1,356,269606,23147,54779,636
    其中:对联营企业和合营企业的投资收益(67,560)46.01%(117,290)(90,752)(20,717)76,830
营业利润11,872,28611.45%6,037,7253,389,4852,340,9242,584,703
利润总额11,831,99111.43%6,015,6093,369,3762,336,9692,580,824
减:所得税费用2,131,73124.24%879,662383,126425,559247,143
净利润9,700,2608.96%5,135,9472,986,2501,911,4092,333,681
减:非控股权益93,5115.19%38,79226,01556,85873,158
股东净利润9,606,7499.00%5,097,1552,960,2351,854,5512,260,523

市场价值指针
每股收益 (元) *3.2708.64%1.7501.0600.8101.590
每股派息 (元) *0.98310.16%0.5170.3630.3370.580
每股净资产 (元) *18.57018.00%13.02013.30810.49015.186
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容